Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Foghorn Therapeutics Inc (FHTX)

Foghorn Therapeutics Inc (FHTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Foghorn Therapeutics Inc 500 Technology Square Ste 700 Cambridge MA 02139 USA

https://foghorntx.com Employees: 112 P: 617-586-3100

Sector:

Medical

Description:

Foghorn Therapeutics Inc. engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system. Foghorn Therapeutics Inc. is based in CAMBRIDGE, Mass.

Key Statistics

Overview:

Market Capitalization, $K 306,506
Enterprise Value, $K 251,056
Shares Outstanding, K 56,551
Float, K 52,264
% Float 92.42%
Short Interest, K 1,179
Short Float 2.08%
Days to Cover 5.33
Short Volume Ratio 0.58
% of Insider Shareholders 7.58%
% of Institutional Shareholders 61.55%

Financials:

Annual Sales, $ 22,600 K
Annual Net Income, $ -86,620 K
Last Quarter Sales, $ 8,150 K
Last Quarter Net Income, $ -15,850 K
EBIT, $ -86,520 K
EBITDA, $ -88,010 K

Growth:

1-Year Return 0.93%
3-Year Return -10.41%
5-Year Return -67.15%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 0.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.25 on 11/05/25
Next Earnings Date 03/05/26 [--]
Earnings Per Share ttm -1.13
EPS Growth vs. Prev Qtr 10.71%
EPS Growth vs. Prev Year 19.35%
Annual Dividend & Yield (Paid) 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%

FHTX Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % 0.00%
Return-on-Assets % -29.62%
Profit Margin % -383.27%
Debt/Equity 0.00
Price/Sales 13.91
Price/Cash Flow N/A
Price/Book N/A
Book Value/Share -1.59
Interest Coverage -1.82
60-Month Beta 3.02
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar